US "tweens" using more medicines

12 November 2007

America's "tweens" age group more than doubled use of type 2 diabetes medications between 2002 and 2005, with girls aged 10 and 14 years showing a 166% increase. The likely cause was said to be obesity, which is closely associated with type 2 diabetes.

The finding is included in a study of chronic medication use in children aged five to 19 reported at the annual meeting of the American Public Health Association by researchers from the Saint Louis University School of Medicine and School of Public Health and pharmacy benefit manager Express Scripts. In addition to diabetes, utilization patterns for blood pressure, cholesterol, asthma and depression medications were also examined.

"Across every chronic medication class we examined over this four year period of time, children's use increased, with varying patterns of growth across males and females and age groups," said Emily Cox, senior director of research at Express Scripts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight